Heqet Therapeutics is the first company to advance a microRNA-based therapy for cardiac regeneration into clinical development, addressing the core limitation in current heart failure treatments: the inability to restore lost cardiomyocytes.

Our approach is grounded in a growing industry momentum around non-coding RNAs—validated by recent billion-euro deals such as Novo Nordisk’s acquisition of Cardior and Eli Lilly’s partnership with HAYA Therapeutics. Scientific consensus is also accelerating: the 2024 Nobel Prize in Medicine recognized the discovery of microRNAs, further affirming their therapeutic potential.

The project is led by Prof. Mauro Giacca, a world authority in cardiovascular science, and supported by strategic collaborations with King’s College London and leading CROs—ensuring both scientific depth and translational strength.